Starting Metabolic State People with more significant insulin resistance or metabolic dysregulation may experience a different timeline
These enzymes are divided into eighteen families and forty-four subfamilies, with six enzymes, CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 being responsible for more than 90% of the metabolizing capacity of the CYP450 enzymes [23]
Here's what typical patients experience: Week 1-2: Minimal Scale Changes, Major Benefits Expected Fat Loss: 1-2 lbs Muscle Gain: 0-0.5 lbs What's Happening: Sleep quality dramatically improves Energy levels increase Recovery from workouts noticeably better Some initial water weight loss GH levels elevating and fat mobilization beginning Week 3-4: Scale Starts Moving Expected Total Fat Loss: 3-5 lbs Muscle Gain: 0.5-1 lb What's Happening: Consistent fat loss becoming evident Face appears less puffy Slight improvements in how clothes fit Strength increasing in gym Mental clarity and mood improving Week 5-8: Visible Body Composition Changes Expected Total Fat Loss: 8-12 lbs Muscle Gain: 1-2 lbs What's Happening: Clothes fitting noticeably looser Waistline reducing by 1-2 inches Muscle definition starting to show Others commenting on changes Photos show clear difference from start Week 9-16: Major Transformation Expected Total Fat Loss: 15-25 lbs Muscle Gain: 3-5 lbs What's Happening: Dramatic reduction in waist/hip measurements (3-4 inches) Stubborn fat areas finally shrinking Significant muscle definition visible Friends/family amazed by transformation May need new wardrobe Week 17-24: Peak Transformation Expected Total Fat Loss: 25-40+ lbs Muscle Gain: 5-8 lbs What's Happening: Total body transformation complete Visible abs/muscle separation 4-6+ inch waist reduction Before/after photos look like different people Optimal body composition achieved "More energy throughout the day and improved life in other ways
Side effects can persist after a dose change Because GLP1 levels taper gradually rather than dropping to zero, symptoms can continue for days or even weeks after a dose change
Mechanistically, GLP-1RA may benefit patients with OSA through multiple pathways, including reductions in systemic inflammation and adiposity
No randomised controlled trials
